Results 111 to 120 of about 44,894 (310)

Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model

Genetics in Medicine, 2018
Genotyping CYP2D6 is important for precision drug therapy because the enzyme it encodes metabolizes approximately 25% of drugs, and its activity varies considerably among individuals.
Seung‐been Lee, M. Wheeler, K. Patterson, Sean McGee, R. Dalton, E. Woodahl, A. Gaedigk, K. Thummel, D. Nickerson   +8 more
semanticscholar   +1 more source

Enantioselective analysis of metoprolol in plasma of hypertensive patients undergoing long-term therapy: Insights for personalized medicine [PDF]

BioImpacts
Introduction: Metoprolol is therapeutically formulated as a racemate with stereoselective pharmacokinetics influenced by CYP2D6 polymorphism. Understanding enantioselective disposition is critical for optimizing therapy in hypertensive patients ...
Behrouz Seyfinejad, Kimiya Jouyban, Jalil Houshyar, Amirreza Jabbaripour Sarmadian, Abolghasem Jouyban   +4 more
doaj   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, EarlyView.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source

Allelic variants of the cyp2d6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela

Revista Peruana de Medicina Experimental y Salud Pública, 2015
The aim of this study was to determine the CYP2D6: * 4, * 6 and * 10 gene variants frequency and to predict the metabolizer phenotype in a sample of 145 unrelated apparently healthy individuals residing in the state of Aragua, Venezuela.
Carlos Flores-Angulo, Cecilia Villegas, Yuselin Mora, José Antonio Martínez, Teresa Oropeza, Nancy Moreno   +5 more
doaj   +1 more source

Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics

Journal of Personalized Medicine, 2018
The seminal paper on the CYP2D6 Activity Score (AS) was first published ten years ago and, since its introduction in 2008, it has been widely accepted in the field of pharmacogenetics.
A. Gaedigk, J. Dinh, Hyunyoung Jeong, B. Prasad, J. S. Leeder   +4 more
semanticscholar   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Succinic acid inhibits the activity of cytochrome P450 (CYP450) enzymes

Pharmaceutical Biology, 2020
Context Succinic acid, extracted from amber, is widely used in cardiovascular therapy. Objective The effect of succinic acid on the activity of cytochrome P450 (CYP450) enzymes was investigated in this study.
Hao Wang, Bingyan Xia, Mei Lin, Yongpeng Wang, Bin Sun, Yuzhu Li   +5 more
doaj   +1 more source

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

European Journal of Human Genetics, 2023
L. Beunk, M. Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne M. Buunk, H. Guchelaar, E. Houwink, A. Risselada, G. Rongen, R. V. van Schaik, J. Swen, D. Touw, R. van Westrhenen, V. Deneer, J. van der Weide   +14 more
semanticscholar   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron

Clinical pharmacology and therapy, 2017
5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and vomiting.
G. Bell, K. Caudle, M. Whirl-Carrillo, R. Gordon, Keiko Hikino, C. Prows, A. Gaedigk, J. Agúndez, S. Sadhasivam, T. E. Klein, M. Schwab   +10 more
semanticscholar   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source